Nautilus Biotechnology (NAUT) Treasury Shares (2020 - 2021)

Nautilus Biotechnology (NAUT) posted Treasury Shares of $22.2 million for Q1 2021, little changed sequentially from $22.2 million in Q4 2020.

Nautilus Biotechnology (NAUT) Treasury Shares (2020 - 2021) Analysis & Trends

Nautilus Biotechnology has reported Treasury Shares for 2 years, with the latest figure at $22.2 million in Q1 2021.

Quarterly Treasury Shares changed N/A year-over-year to $22.2 million in Q1 2021, while the trailing twelve-month figure through Mar 2021 was $22.2 million (changed N/A YoY) and the FY2020 annual result came in at $22.2 million, changed N/A from the prior year.
Treasury Shares was little changed at $22.2 million in Q1 2021 per NAUT's latest filing, from $22.2 million in the prior quarter.
Over five years, Treasury Shares peaked at $22.2 million in Q2 2020 and troughed at $22.2 million in Q2 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Treasury Shares (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	36.40 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	8.96 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	2.72 Mn
10	Nautilus Biotechnology	120.16 Mn	120.16 Mn	175,000.00	-

Download Data